Material: Crystal

Sports Technology Deal Tombstone

Crystal deal tombstone marking the acquisition of sports data and technology company Second Spectrum. Second Spectrum is the official provider of player tracking data for the Premier League, NBA, and MLS.

(21AKL260)
1 Image

Eye Care Deal Toy

Crystal deal toy marking a capital raise by eye care firm Visioneering Technologies.

(21ALJ208)
1 Image

CLO Crystal Commemorative

Crystal commemorative marking collateralized loan obligations (CMO’s) issued by investment firm Bardin Hill.

(21AKL151)
2 Images
Top view of crystal deal toy commemorating the issue of CMO's by Bardin Hill, a global investment firm.

Series A Financing Deal Toy

Crystal deal toy commemorating Series A financing for Interius BioTherapeutics,  a preclinical stage gene therapy firm.

(21AKL266)
2 Images
Crystal deal tombstone celebrating Series A financing for Interius BioTherapeutics. The gene therapy developer is based in Philadelphia.

Oil Drop-Themed Financial Tombstone

Crystal financial tombstone marking a US$750 million syndicated loan facility entered into by Santos. The Australian oil and gas provider will use the facility to refinance an existing facility used to acquire ConocoPhillips’ northern Australian and Timor-Leste assets.

(21AJH049)
2 Images
Crystal deal tombstone commemorating a loan facility  for Australian oil and gas provider Santos.

Sports Car-Themed Deal Tombstone

Crystal deal tombstone marking the acquisition of Nettix, an operator of classified sites in Finland, including ones for cars, real estate, and employment opportunities.

(21LJW065)
1 Image

Proxy Statement Crystal Commemorative

Custom crystal commemorative, with an “open book” design, marking the first proxy statement by Rocket Companies. The Detroit-based corporation operates through consumer brands such as Rocket Mortgage and Rocket Homes.

(21AKL209)
1 Image

ASX IPO Crystal Commemorative

Crystal commemorative marking the initial public offering of Australian biotech firm Chimeric Therapeutics. The firm is developing a class of cell therapy drugs for the treatment of cancer.

(21ALJ210)
2 Images
Back view of custom crystal celebrating the initial public offering on the Australia Securities Exchange of Chimeric Therapeutics.